Quantitative G6PD point-of-care test can be used reliably on cord blood to identify male and 2 female newborns at increased risk of neonatal hyperbilirubinaemia: a mixed method study

28 Introduction: New point-of-care (POC) quantitative G6PD testing devices developed to provide safe 29 radical cure for P. vivax malaria may be used to diagnose G6PD deficiency in newborns at risk of severe 30 neonatal hyperbilirubinaemia, improving clinical care, and preventing related morbidity and mortality. 31 Methods: We conducted a mixed-methods study analyzing technical performance and usability of the 32 “STANDARD G6PD” Biosensor when used by trained midwives on cord blood samples at two rural 33 clinics on the Thailand-Myanmar border. 34 Results: In 307 cord blood samples, the Biosensor had a sensitivity of 1.000 (95%CI 0.859-1.000) and a 35 specificity of 0.993 (95% CI 0.971-0.999) as compared to gold standard spectrophotometry to diagnose 36 G6PD deficient newborns using a receiving operator characteristic (ROC) analysis-derived threshold of 37 ≤4.8IU/gHb. The Biosensor had a sensitivity of 0.727 (95%CI: 0.498-0.893) and specificity of 0.933 38 (95%CI: 0.876-0.969) for 30-70% activity range in females using ROC analysis-derived range of 4.9 to 39 9.9IU/gHb. These thresholds allowed identification of all G6PD deficient neonates and 80% of female 40 neonates with intermediate phenotypes. 41


INTRODUCTION 53
Pathologically increased levels of bilirubin during the first week of life, i.e. neonatal 54 hyperbilirubinaemia (NH), are common and dangerous for the developing brain. The most severe form 55 of NH, kernicterus, causes neurological sequelae in >80% of neonates (56/100,000 live births globally, 56 [1]). Every year, an estimated twenty-four million newborns are at risk of NH-related adverse outcomes 57 with three-quarters of mortality occurring in sub-Saharan Africa and South Asia [1,2]. These 58 preventable deaths and disabilities disproportionally affect neonates where universal health care and 59 treatment options are scarce, if not absent [3]. 60 Several genetic and clinical factors influence the timing and evolution of NH, including G6PD deficiency, 61 ABO blood group incompatibility, prematurity/low birth weight and sepsis [4]. Early identification of 62 these risk factors can dramatically improve neonatal clinical management during the first days of life 63 [5]. 64 The enzymatic defect of G6PD deficiency, caused by mutations on the X-linked G6PD gene, is a known 65 risk factor for increased levels of bilirubin after birth and it is associated with susceptibility to drug-66 induced haemolysis [6]. Risk of severe NH is increased in both deficient and heterozygous newborns 67 with abnormal phenotypes [7-9] and universal neonatal screening of G6PD deficiency is supported by 68 WHO in populations where more than 3-5% of males are affected [10]. 69 G6PD deficiency is particularly prevalent among neonates from tropical regions [11], where clinical 70 care is often provided in a non-tertiary hospital or clinic context. Knowledge of G6PD status by medical 71 staff and parents can aid in avoiding potentially haemolytic antibiotics or other agents (such as 72 naphthalene), improved follow-up, and heightened awareness of signs and symptoms of severe NH. 73 G6PD deficiency is very common among the Karen and Burman population along the Thailand-74 Myanmar border (9-18% in males, [12]) where it is associated with an increased risk to develop NH 75 requiring phototherapy both in G6PD deficient (over 4-fold [13]) and in heterozygous females (over 2-76 fold [5]) as compared to wild type genotype neonates. In a recent study, screening of G6PD by 77 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 13, 2022. ; https://doi.org/10.1101/2022.07.03.22277173 doi: medRxiv preprint qualitative Fluorescent Spot Test (FST) on cord blood failed to identify almost 10% of G6PD deficient 78 neonates [14]. A mixed-methods study was conducted to evaluate both the technical performance of the "G6PD 86 STANDARD" (SD Biosensor, Korea) test (henceforth "Biosensor") and its usability by midwives in a non-87 tertiary setting. G6PD enzymatic activity and haemoglobin concentration measured by the device were 88 compared to the gold standard reference spectrophotometric assay and haematology analyser, 89 respectively. Performance of the G6PD fluorescent spot test (FST) currently used routinely at the point-90 of-care, was also compared to the reference and new test. 91 Following local staff training, user proficiency was assessed before study start; usability was explored 92 using focus group discussions (FGD) at the end of the study. 93 Study setting and population 94 The study was conducted in SMRU clinics situated along the Thailand-Myanmar border in Tak  were informed about the study at regular antenatal care visits in the 3 rd trimester. Informed consent 101 procedures and eligibility assessments for mothers were completed before labour commenced. 102 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 13, 2022. Two milliliters of cord blood were collected into EDTA from the umbilical cord using an established 110 SMRU SOP. An aliquot of anticoagulated blood was used by the midwives in the delivery room for the 111 Biosensor following manufacturer's instructions within one hour of collection (Appendix 1). Tests were 112 repeated if the test result was an error or "HI" (a result obtained when G6PD activity is very high, 113 outside the instrument analytic range). High-level and low-level Biosensor controls were run weekly or 114 monthly (depending on availability) from April 2020 until May 2021. 115 An aliquot of anticoagulated blood was analysed by G6PD fluorescent spot test (FST) at the clinical 116 laboratory. The remaining blood was stored at 4°C until shipment to the central SMRU laboratory on 117 the same day. 118 Gold standard reference testing for G6PD and haemoglobin were performed by spectrophotometric 119 assay and haematology analyser (with complete blood and reticulocyte counts), respectively, at the 120 SMRU central laboratory. 121 G6PD spectrophotometric assay was performed using Pointe Scientific kits (assay kit # G7583-180, Lysis 122 Buffer # G7583-LysSB). Kinetic determination of G6PD activity at 340 nm was performed using a 123 SHIMAZU UV-1800 spectrophotometer with temperature controlled cuvette compartment (30°C). 124 Samples were analysed in double and mean activity was expressed in IU/gHb using the Hb 125 concentration obtained by complete blood count analysis. The final result was calculated using 126 manufacturer's Temperature Control Factor of 1.37. Two controls (Normal, Intermediate or Deficient; 127 Analytic Control Systems, Inc. USA) were analysed at every run and results compared to expected 128 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 13, 2022. ; https://doi.org/10.1101/2022.07.03.22277173 doi: medRxiv preprint ranges provided by manufacturer. Complete blood count was performed using a CeltacF MEK-8222K 129 haematology analyser (Nihon Kohden, Japan). Three-levels quality controls were run every day and 130 device maintenance and calibration were performed regularly. Reticulocytes were analysed by 131 microscopy after staining with supervital staining Crystal Violet. 132 Buffy coat recovered from whole blood after centrifugation was stored at -20°C for later DNA 133 extraction using standard columns kit (Favorgen Biotech, Taiwan). Genotyping for G6PD common 134 Midwives of WPA and MKT SMRU clinics were trained for use of Biosensor and were eligible to 142 participate in the usability component of the study following informed consent. Two to four training 143 sessions were provided at each clinic in the local language by an experienced laboratory technician 144 (author LA). The sessions lasted from 1 to 2 hours and included a short introduction about the test, a 145 practical demonstration using imitation blood, and supervised use of the biosensor by each midwife. 146 Midwives were allowed to practice the procedure the week following the training prior to taking a user 147 proficiency test. The proficiency test was administered by author LA in the local language and it 148 consisted of a questionnaire (modified from a questionnaire developed by PATH 149 (https://www.finddx.org/wp-content/uploads/2020/09/PATH_STANDARD-G6PD-User-Competency-150 Assessment-quiz_08oct19.pdf) and direct observation of two consecutive tests. Midwives were asked 151 to explain out-loud their actions while performing the first test. The proficiency test was analysed by 152 authors GB and GG and midwives who scored <85% were re-trained before study start. A visual aid 153 with all critical steps of the procedure was printed and available in the delivery room during the study. 154 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 13, 2022. Blood analysis for assessment of neonatal hyperbilirubinaemia 169 Routine clinical care for newborns included at least one total serum bilirubin (TSB) test before 170 discharge (around 48h of life) using capillary blood measured on-site by the rapid quantitative 171 bilirubinometer BR-501 (Apel Co. Ldt, Japan). 172 173 Sample size and statistical analyses 174 The expected prevalence of G6PD deficiency in the population living at the border is 9-18% in males 175 and 2-4% in female [12,16] corresponding to approximately 20-30% heterozygous females, 60% of 176 whom have intermediate activity [18]. Assuming that the proportion of females and males in the 177 neonate population is 50%, 9% were expected to be G6PD deficient and 7% to be G6PD intermediate. 178 In order to obtain 95% CI of the limits of agreement within 0.5 SD of the difference, about 31 neonates 179 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 13, 2022. At the outset of the study, the research team engaged the local population through a local ethics and 202 research advisory committee, the Tak Province Community Advisory Board, Thailand. This group is 203 comprised of community leaders, and were asked to advise on study design, process, and outcomes 204 of interest, and subsequently approved the study (TCAB201904). 205 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 13, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 13, 2022. ; https://doi.org/10.1101/2022.07.03.22277173 doi: medRxiv preprint The cord blood-specific 30% spectrophotometric threshold identified all the hemizygous male and 237 homozygous female newborns ( Figure 1A).  is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 13, 2022. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 13, 2022. ; https://doi.org/10.1101/2022.07.03.22277173 doi: medRxiv preprint differences in activity (Biosensor -Spectrophotometry) were observed in the last 4-8 months of use as 313 compared to the first 12 months (Supplementary Figure 1). 314 Biosensor training, user proficiency and usability assessment  Table 3. Overall satisfaction was high, although staff were concerned with 338 invalid results, and found it challenging to dedicate one member of the team to perform the biosensor 339 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 13, 2022. ; https://doi.org/10.1101/2022.07.03.22277173 doi: medRxiv preprint test in the delivery room in the busy postpartum period. In terms of learnability, the midwife assistants 340 reported learning the device more easily, though some were anxious about missing steps. The senior 341 staff were anxious about mistakes and clotted blood, and reported the need to refer to the instructions 342 as a problem. Contrary to the positive expressions to keep using the device at the clinic, the midwives' 343 willingness to use the device was not high and they requested a dedicated staff to perform the test or 344 the test to be done in the laboratory. In terms of suitability and future use, the midwives found the 345 results clinically useful and a valuable diagnostic tool in both their setting and field clinics. However, 346 they were concerned about neglecting clinical care while doing a laboratory test, the cost of the device, 347 and emphasized the need for good training. 348 Table 3. Selected quotes by theme from focus group discussions. 349

Theme Quotes
A. Satisfaction "It is very good for the children. It is good to know if the child has G6PD deficiency or not from birth. The advantage of the device is that it can detect the children without having to do a heel stick on the baby. On the other hand, there is an increase in work…. But now that we are good at using it, it's fine." [FGD1] "Sometimes if someone is doing the test by using the device it means there are fewer staffs to be with mothers and babies which is not good." [FGD1] B. Learnability "After the one-time training, we had 1 or 2 times experiences practically. Then we can do it." [FGD2] "I am really scared I will forget the steps." [FGD2] "We have to look at the book very often, if not we forget the process of what to put and how to put it." [FGD1] C. Willingness "Facilitator: Yes. What do you think about keeping on using this device in the future? Participant: Of course. It is good. Participant: Yes, it is good. But if we can have a specific staff to do it then it will be better." "To make changes, take out the blood and send it to the lab. Then only lab staff have to do that." [FGD1] D. Suitability & Future Use "Because we can know that early, we can have counseling with the parents about the chances of their children getting yellow skin. We can take time to counsel." [FGD1] "Because we can know the right result of the G6PD deficiency in a short time. Especially for the clinic which doesn't have a lab then it is difficult to know the G6PD status. But with this device, they will only need to take a little blood from the baby and they can know the result of G6PD." [FGD2] 350 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 13, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 13, 2022. While the Biosensor provided a numeric result in 94.5% of cases, in few cases an "error" message or a 382 "HI" result was obtained which, according to the protocol, required re-analysis of the sample. Samples 383 that tested "HI" were confirmed to be normal, both phenotypically by spectrophotometry and by 384 genotype (all wild type). In routine practice it will not be needed to repeat the test in samples showing 385 "HI" result should the manufacturers include this information in the instructions for use. 386 The usability component highlighted important themes to be taken into consideration for future use 387 of the Biosensor at birth. The midwives have been involved in previous research regarding neonatal 388 jaundice and appreciated the importance of early G6PD diagnosis to identify newborns most at risk of 389 neonatal hyperbilirubinaemia and to facilitate optimal clinical care and parental counselling. The non-390 invasive nature of cord blood analysis was considered an advantage. In this setting, the SMRU 391 midwives recommended that the test be performed by dedicated staff or by the available laboratory 392 to assure appropriate clinical care is provided to the newborns and mothers; nevertheless, they 393 estimated that in more rural contexts it may be appropriate for trained birth attendants to perform 394 the test. Of note, midwives considered their reliance on reading the visual aid while performing the 395 test (which is standard practice in laboratories) a weakness and this aspect might need to be taken 396 into account when training clinic field staff. Usability results obtained here might not be generalizable 397 to every other context but there are data being collected in several rural and community-based 398 settings that corroborate ease of use of this device to guide malaria treatment after appropriate 399 training [26,35,36] . 400 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 13, 2022. It is very likely that performance and reference ranges observed here in cord blood could apply to 412 neonatal capillary or venous blood collected within the first 24 hours of life but this was not evaluated 413 during the study. 414 The study was conducted in a period critically influenced by the COVID-19 pandemic. Travel restrictions 415 resulted in a delayed study start, reduced enrolment in one clinic (WPA), and a protracted enrolment 416 duration of the study overall. Fewer than planned FGD were conducted-including planned discussions 417 at key time points during the study-and they occurred in a single clinical site providing a possibly 418 narrower point of view on the usability topics explored. Additional staff stressors and human resource 419 limitations due to COVID-19 and the political unrest in 2021 were not assessed but may have 420 influenced the results of both the technical and usability components of the study. 421 422 CONCLUSIONS 423 The "STANDARD G6PD" Biosensor is a reliable POC tool to support the perinatal care of newborns at 424 higher risk of neonatal hyperbilirubinemia by demonstrating very high sensitivity in identification of 425 deficient newborns and high sensitivity in identification of female newborns with intermediate activity. 426 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 13, 2022. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 13, 2022. ; https://doi.org/10.1101/2022.07.03.22277173 doi: medRxiv preprint CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 13, 2022. ; https://doi.org/10.1101/2022.07.03.22277173 doi: medRxiv preprint Quantitative G6PD point-of-care test can be used reliably on cord blood to identify male and female newborns at increased risk of neonatal hyperbilirubinaemia: a mixed method study A) 30% activity B) 70% activity